Aplaviroc

Aplaviroc

Drugbox
IUPAC_name = 4-(4-{ [(3"R")-1-butyl-3- [("R")-cyclohexylhydroxymethyl] -2,5-dioxo- 1,4,9-triazaspiro [5.5] undecan-9-yl] methyl}phenoxy)benzoic acid



width = 300
CAS_number = 461023-63-2
ATC_prefix =
ATC_suffix =
PubChem = 3001322
DrugBank =
C=33|H=43|N=3|O=6
molecular_weight = 577.711 g/mol
smiles = CCCCN1C(=O) [C@H] (NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O) [C@@H] (C5CCCCC5)O
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Aplaviroc (INN, codenamed AK602 and GSK-873140) was a CCR5 entry inhibitor developed for the treatment of HIV infection. [http://www.retroconference.org/2004/cd/PDFs/540.pdf] [ [http://jvi.asm.org/cgi/content/abstract/79/4/2087 Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor {gamma}-Chain-Knocked-Out AIDS Mouse Model - Nakata et al. 79 (4): 2087 - The Journal of Virology ] ]

In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. [cite web |url=http://www.aidsmeds.com/drugs/aplaviroc.htm |title=Aplaviroc (GSK-873,140) |date=October 25, 2005 |publisher=AIDSmeds.com |accessdate=2008-09-05] [cite journal |author=Nichols WG, Steel HM, Bonny T, "et al" |title=Hepatotoxicity observed in clinical trials of aplaviroc (GW873140) |journal=Antimicrob Agents Chemother |volume=52 |issue=3 |pages=858–65 |year=2008 |month=March |pmid=18070967 |pmc=2258506 |doi=10.1128/AAC.00821-07 |url=] Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; [cite web |url=http://www.thebody.com/content/treat/art39205.html |title=The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy |date=December 19, 2006 |author=Moyle, Graeme |publisher=The Body |accessdate=2008-09-05] the ASCENT study, one of the discontinued trials, showed aplaviroc to be inferior to efavirenz as the third component of a three-drug regimen. [cite journal |author=Currier J, Lazzarin A, Sloan L, "et al" |title=Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study |journal=Antivir Ther (Lond.) |volume=13 |issue=2 |pages=297–306 |year=2008 |pmid=18505181 |doi= |url=]

References

Further reading

*cite journal |author=Horster S, Goebel FD |title=Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge |journal=Infection |volume=34 |issue=2 |pages=110–3 |year=2006 |month=April |pmid=16703305 |doi=10.1007/s15010-006-6206-1 |url=


Wikimedia Foundation. 2010.

Игры ⚽ Нужна курсовая?

Look at other dictionaries:

  • CCR5 receptor antagonists — are a class of small molecules that antagonize the CCR5 receptor. The C C motif chemokine receptor CCR5 is involved in the HIV entry process. Hence antagonists of this receptor have potential therapeutic applications in the treatment of HIV… …   Wikipedia

  • GlaxoSmithKline — Infobox Company | company name = GlaxoSmithKline company company type = Public (lse|GSK nyse|GSK) company slogan = Do more, feel better, live longer foundation = 2000, by merger of Glaxo Wellcome and SmithKline Beecham location = flagicon|UK… …   Wikipedia

  • CCR5 — Chemokine (C C motif) receptor 5 Rendering based on PDB 1ND8 …   Wikipedia

  • Entry inhibitor — Entry inhibitors, also known as fusion inhibitors, are a class of antiretroviral drugs, used in combination therapy for the treatment of HIV infection. This class of drugs interferes with the binding, fusion and entry of an HIV virion to a human… …   Wikipedia

  • Zidovudine — AZT redirects here. For other uses, see AZT (disambiguation). Zidovudine Systematic (IUPAC) name …   Wikipedia

  • Antiretroviral drug — HAART redirects here. For UK estate agency Haart, see Spicerhaart. Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When several such drugs, typically three or four, are taken in combination, the …   Wikipedia

  • Didanosine — Systematic (IUPAC) name 9 [(2R,5S) 5 (hydroxymethyl)oxolan 2 yl] 6,9 dihydro 3H purin 6 one Clinical data AHFS/Drugs.c …   Wikipedia

  • Zalcitabine — Systematic (IUPAC) name 4 amino 1 ((2R,5S) 5 (hydroxymethyl)tetrahydrofuran 2 yl)pyrimidin 2(1H) one Clinical data AHFS/Drugs.com …   Wikipedia

  • Stavudine — Systematic (IUPAC) name 1 ((2R,5S) 5 (hydroxymethyl) 2,5 dihydrofuran 2 yl) 5 methylpyrimidine 2,4(1H,3H) dione Clinical data AHFS/Drugs.com …   Wikipedia

  • Emtricitabine — Systematic (IUPAC) name 4 amino 5 fluoro 1 [(2S,5R) 2 (hydroxymethyl) 1,3 oxathiolan 5 yl] 1,2 dihydropyrimidin 2 one Clinical data …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”